VALUE OF UNIVERSAL CHILDHOOD VARICELLA VACCINATION IN SLOVENIA

Abstract

Background. In 1974 effective and safe vaccine against varicella was developed. Vaccination is recomended for universal childhood immunisation in some of west European countries and in the United States. The aim of the study was to perform economic analysis of universal childhood vaccination against varicella in Slovenia.Methods. We examined hypothetical birth cohort of 5800 persons followed from birth to their 30th birthday and calculated the cost-benefit ratio for varicella vaccination program. We assumed that one dose of vaccine would be given to 15-monthold children along with measles, mumps and rubella vaccination. It was also assumed that 95% of children would be vaccinated, that vaccine efficacy would be 90%, that vaccine induced immunity would be lifelong and that the program would have no effect on either the incidence rate or severity of herpes zoster. For both disease and vaccine we measured the direct medical cost and indirect cost.Results. Indirect cost represented major part compared to medical cost. The benefit to cost ratio was 0.89.Conclusions. Considering major assumptions in this analysis, there is no financial benefits from vaccinating all children against varicella in our country.

Keywords

• chickenpox
• vaccination
• cost-benefit analysis